

BEST AVAILABLE COPY



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07C 209/40, 211/42</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/27050</p> <p>(43) International Publication Date: 25 June 1998 (25.06.98)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/HU97/00083</p> <p>(22) International Filing Date: 15 December 1997 (15.12.97)</p> <p>(30) Priority Data: P 96 03493 18 December 1996 (18.12.96) HU</p> <p>(71) Applicant (for all designated States except US): RICHTER GEDEON VEGYÉSZETI GYÁR RT. [HU/HU]; Gyömrői út 19-21, H-1103 Budapest X (HU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VUKICS, Krisztina [HU/HU]; Bocskai út 43-45-12 lépcsőh II emelet 260, H-1113 Budapest (HU). FODOR, Tamás [HU/HU]; Andrássy út 3, H-1061 Budapest (HU). FISCHER, János [HU/HU]; Úri u. 33, H-1014 Budapest (HU). FELLEGVÁRI, Irén [HU/HU]; Zemplén Győző u. 1, H-1038 Budapest (HU). LÉVAI, Sándor [HU/HU]; Ipar u. 20, H-2051 Biatorbágy (HU).</p> <p>(74) Common Representative: RICHTER GEDEON VEGYÉSZETI GYÁR RT.; Gyömrői út 19-21, H-1103 Budapest X. (HU).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/HU97/00083</p> <p>(22) International Filing Date: 15 December 1997 (15.12.97)</p> <p>(30) Priority Data: P 96 03493 18 December 1996 (18.12.96) HU</p> <p>(71) Applicant (for all designated States except US): RICHTER GEDEON VEGYÉSZETI GYÁR RT. [HU/HU]; Gyömrői út 19-21, H-1103 Budapest X (HU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VUKICS, Krisztina [HU/HU]; Bocskai út 43-45-12 lépcsőh II emelet 260, H-1113 Budapest (HU). FODOR, Tamás [HU/HU]; Andrássy út 3, H-1061 Budapest (HU). FISCHER, János [HU/HU]; Úri u. 33, H-1014 Budapest (HU). FELLEGVÁRI, Irén [HU/HU]; Zemplén Győző u. 1, H-1038 Budapest (HU). LÉVAI, Sándor [HU/HU]; Ipar u. 20, H-2051 Biatorbágy (HU).</p> <p>(74) Common Representative: RICHTER GEDEON VEGYÉSZETI GYÁR RT.; Gyömrői út 19-21, H-1103 Budapest X. (HU).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(21) International Application Number: PCT/HU97/00083</p> <p>(22) International Filing Date: 15 December 1997 (15.12.97)</p> <p>(30) Priority Data: P 96 03493 18 December 1996 (18.12.96) HU</p> <p>(71) Applicant (for all designated States except US): RICHTER GEDEON VEGYÉSZETI GYÁR RT. [HU/HU]; Gyömrői út 19-21, H-1103 Budapest X (HU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VUKICS, Krisztina [HU/HU]; Bocskai út 43-45-12 lépcsőh II emelet 260, H-1113 Budapest (HU). FODOR, Tamás [HU/HU]; Andrássy út 3, H-1061 Budapest (HU). FISCHER, János [HU/HU]; Úri u. 33, H-1014 Budapest (HU). FELLEGVÁRI, Irén [HU/HU]; Zemplén Győző u. 1, H-1038 Budapest (HU). LÉVAI, Sándor [HU/HU]; Ipar u. 20, H-2051 Biatorbágy (HU).</p> <p>(74) Common Representative: RICHTER GEDEON VEGYÉSZETI GYÁR RT.; Gyömrői út 19-21, H-1103 Budapest X. (HU).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: PROCESS FOR PREPARING A NAPHTALENAMINE DERIVATIVE</p>				
<p>(57) Abstract</p> <p>The present invention relates to a process for preparing cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine and its acid addition salts wherein N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphtalene-1-en]-amine-N-oxide is hydrogenated in an inert solvent in the presence of a catalyst, then the resulting mixture is treated with alcoholic solution of a mineral acid, the resulting cis-racemic acid addition salt is converted to the free base by known methods, resolved and the resulting cis-(+)-base of formula (II) is converted to an acid addition salt. N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphtalene-1-en]amine-N-oxide is also disclosed.</p>				


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR PREPARING A NAPHTALENAMINE DERIVATIVE

The present invention relates to a novel process for preparing a naphthalenamine derivative, the compound of formula (I) (chemical name: *cis*-(1*S*)-*N*-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine) hereinafter referred as to "sertraline" and its acid addition salts.



A novel intermediar used in this process, the compound of formula (II) is also disclosed.



It is known that sertraline hydrochloride is a valuable pharmaceutically active substance, and the pharmaceutical composition containing this compound is applicable in the treatment of depression and other dependence and anxiety-related disorders (See U.S. Patent Nos. 4,536,518 and 5,248,699).

The preparation of sertraline is reported in the above mentioned U.S. Patent No. 4,536,518 (or the equivalent Hungarian patent No. 182,224). The essence of the herein described process is, that 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalene-1-one, which can be prepared in a complicated reaction way of several steps is condensed with methylamine to the Schiff base in the presence of titanium tetrachloride as catalyst. The Schiff base is hydrogenated in the presence of palladium on carbon as catalyst, and a mixture of the cis/trans isomers of N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride is obtained, where the cis/trans ratio is about 70:30. The mixture of cis/trans isomers is dissolved in a 40 times amount of hot methanol based on the starting tetralone, and the cis isomer in crystalline form can be obtained after the addition of a 30 times amount of diethyl ether. The primary yield is 48 %, which is increased to 68 % by working up the mother liquor obtaining a second crop of the title compound.

The disadvantages of the described process obviously appear from the above survey, namely, the appropriate dihydro-naphthalenone derivative can be prepared only in several steps with difficulties. Moreover, the hydrogenation of the Schiff-base derivative of this compound results in a mixture of cis/ trans isomers. The desired cis-isomer from this mixture can be obtained only in large dilution and using big excess of solvents. The large-scale realization of this process is very disadvantageous, even without mentioning the working time, working power and energy excess made by the big solvent circulation and the work-up of the so-called secondary generation's mother liquor.

So the aim of the present invention is to produce a process which doesn't show the above disadvantages but at the same time gives sertraline or its acid addition salts in a simpler way and in better yield.

During our experiments, we found that reacting the appropriately substituted 3,4-dihydro-naphthalenone derivative, that could be prepared in a simple way, with the

commercially available N-methylhydroxylamine as so far in the literature not reported N-oxide derivative formed, which after isolation could give directly the desired cis-compound in catalytic hydrogenation, which was easily resolved and converted to sertraline.

This recognition is surprising because N-oxide derivatives similar to that compound of Formula (II) are unstable, and it was unexpected that exactly the desired stereoisomer could be obtained by the hydrogenation.

According to the above, the invention relates to a process for preparing cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine of formula (I) and its acid addition salts, in the way, that N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalene-1-en]-amine-N-oxide of formula (II) is hydrogenated in an inert solvent in the presence of a catalyst, then the resulting mixture is treated with alcoholic solution of a mineral acid, the resulting cis-racemic acid addition salt is converted to the free cis-base by standard techniques well-known to those skilled in the art, resolved, then in the required case the cis-(+)-base of formula (I) is converted to the acid addition salt.

According to a preferred version of the process disclosed in the invention, methanol is used as inert solvent, and Raney-Nickel is used as catalyst in the hydrogenation.

According to the process disclosed in the invention, hydrogen chloride in methanol or ethanol is used as alcoholic solution of mineral acid.

Resolution of the racemic compound can be carried out with an optically active acid by standard techniques well-known to those skilled in the art.

The invention also relates to the N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalene-1-en]-amine-N-oxide, which is a new, so far not reported compound.

The N-oxide of formula II can be prepared from 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphtalenone and commercially available N-methylhydroxylamine heating under reflux in an inert solvent, preferably in ethanol in 70-90 % yield.

The starting material [4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphtalenone] can be prepared by the reaction of 1-naphtol and 1,2-dichlorobenzene that gives the starting compound in the presence of aluminum chloride as catalyst in 80 % yield. The above reaction of naphtol is previously reported by Rupinskaya and her co-workers in their article (Zh.Org.Khim. 18(4) 870-8 (1982).

The main advantage of the process of our invention is that the new N-oxide of formula (II) gives the compound of formula (I) in a far better yield compared with the former Schiff-base method. The bigger stability of the N-oxide compared to the Schiff base makes the isolation possible, which can be applied as purification step if required.

Finally, it is important in safety respects that instead of the harmful methylamine the harmless N-methylhydroxylamine is going to be applied.

The process disclosed in our invention is presented by the following examples:

EXAMPLE 1

Cis-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine hydrochloride

11.2 g (35 mmol) of N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphtalene-1-en]-amine-N-oxide was suspended in 200 ml of methanol and hydrogenated over 3-4 g of Raney-Nickel catalyst washed to pH neutral and anhydrous at atmospheric pressure and 25 °C. After the theoretically necessary hydrogen uptake had ceased (5-6 h), the catalyst was filtered, and the methanol

was evaporated. The residue was dissolved in 60 ml of ethanol and 5.1 ml of 6.8 n hydrogen chloride in ethanol was added dropwise to the stirred solution.

The title compound starts immediately crystallising. The suspension was stirred for 3 hours at 0 °C, then filtered and washed with 30 ml of -10 °C ethanol.

Product : 11.5 g (81 %) of the title compound. TLC: Kieselgel-60, ethyl acetate/ methanol/ cc. ammonium hydroxide 10 : 0.5 : 0.25, Rf: 0.54.

Mp: 290-291 °C.

EXAMPLE 2

In like manner to that described in Example 1, the same compound was prepared by hydrogenation using 20 times amount of ethanol based on N-oxide of formula (II) as solvent in the presence of 10 % palladium on carbon as catalyst. The product obtained was identical in every respect with the product of Example 1.

PREPARATION OF THE STARTING MATERIALS

a.) Preparation of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalene-1-on

To a stirred solution of 21.62 g (0.15 mol) of 1-naphtol in 182 g (140 ml) of 1,2-dichloro-benzene 50 g (0.375 mol) anhydrous aluminum chloride was added. The reaction mixture was heated to 100 °C and stirred at this temperature for 1 hour. The mixture was cooled to room temperature and poured into 240 g of ice and 70 ml of cc. hydrochloric acid, then 200 ml of methylene chloride was added. The organic layer was separated and the

aqueous layer was extracted twice with 200 ml of methylene chloride. The combined organic layers were washed with 200 ml of water and stirred with 20 g of celite and 10 g of activated carbon, filtered and the solvents were evaporated in vacuum. To the oily residue (45-50 g) 44 ml of methanol was added. The product crystallized, the suspension was stirred for 5 hours at 0 °C, then filtered and washed twice with 50 ml of -10 °C methanol.

Product: 34.9 g (80 %) of the title compound. TLC: Kieselgel-60, n-hexane/ethanol 10 : 1, Rf: 0.29.

Mp: 99-101 °C.

b.) Preparation of N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphtalene-1-en]-amine-N-oxide [compound of formula (II)]

46.08 g (0.158 mol) of 4-(3,4-dichloro-phenyl)-3,4-dihydro-naphtalene-1-on, 26.45 g (0.317 mol) of N-methylhydroxylamine hydrochloride and 25.98 g (0.317 mol) of anhydrous sodium acetate in 600 ml of ethanol were stirred and heated until boiling. After 6 hour heating under reflux the ethanol was evaporated in vacuum in a 50 °C water bath. To the residue 200 ml of water and 200 ml of methylene chloride were added. The organic layer was washed with 100 ml of water, then the combined aqueous layers were extracted with 100 ml of methylene chloride.

The organic layer was dried on anhydrous sodium sulfate, filtered and the solvent was evaporated in vacuum in a 30 °C water bath. To the residue 65 ml of t-butyl methyl ether was added and stirred for 2 hours at room temperature and then for 4 hours at 0 °C. The product was filtered and washed twice with 30 ml of -10 °C t-butyl methyl ether.

Product : 43.0 g (85 %) of the title compound. TLC: Kieselgel-60, methylene chloride/ methanol 10 : 1, Rf: 0.52.

Mp: 175-179 °C.

Further physical and chemical properties of the product are listed below:

NMR data:

NMR spectrum was recorded on a Varian VXR-300 spectrometer (^1H : 300 Hz) using CDCl_3 as solvent, temperature: 24 °C, reference: $\delta_{\text{TMS}} = 0.00$ ppmn.

^1H -NMR: 2.10-2.30 m (2H) [H-3], 2.50-2.80 m (2H) [H-2], 3.88 s (3H) [H-NMe], 4.12 t (1H) [H-4], 6.83 dd (1H) [H-16], 6.97 d (1H) [H-15], 7.19 d (1H) [H-12], 7.25-7.50 m (3H) [H-6,7,8], 9.63 d (1H) [H-9]

Mass spectroscopic data:

MS spectrum was obtained using a VG-TRIO-2 -spectrometer, ionization mode: EI, electron energy: 70 eV, ion source temperature: 250 °C.

m/z (rel. int. %): 323(6.0) $[\text{M}+4]^+$; 321(33.0) $[\text{M}+2]^+$; 319(49.0) $[\text{M}]^+$; 306(18.0); 304(68.0); 302(100.0); 279(3.0); 277(13.0); 275(21.0); 206(4.0); 204(23.0); 202(29.0); 160(20.0); 128(30.0); 115(33.0)

Infrared data:

Equipment: PERKIN ELMER 1000 spectrophotometer, phase: KBr pellet, resolution: 4 cm^{-1} .

The most characteristic absorption bands (cm^{-1}):

N \rightarrow O 1470, 1201

C = N 1642 (weak)

Ar - Cl 1130, 1077

Ar 1588, 832, 767

Other important absorption bands (cm^{-1}):

2937, 1524, 1353, 1032, 949, 712, 560

Reference example:

Preparation of cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalanamine hydrochloride (sertraline hydrochloride)

10.27 g (30 mmol) of cis-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine hydrochloride described in Example 1 was dissolved in 70 ml of methylene chloride and extracted with 40 ml of 10 % aqueous sodium carbonate. The aqueous layer was extracted with 30 ml of methylene chloride, then the combined organic layers were dried on sodium sulfate and filtered. Methylene chloride was evaporated in vacuum in a 40 °C water bath. The residue was dissolved in 100 ml ethanol, and 4.56 g (30 mmol) R-(-)-mandelic acid was added. The mandelic acid salt crystallized after a few minutes. The resulting suspension was stirred for 6 hours at 25 °C, then filtered and washed with 50 ml of ethanol.

Product: 5.65 g (41 %) of cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtyl-amine mandelate, mp: 189-191 °C.

5.04 g (11 mmol) of the above described mandelic acid salt was mixed with 50 ml of methylene chloride and 30 ml of 2 n aqueous sodium hydroxide. The layers were separated and the aqueous layer was extracted with 20 ml of methylene chloride. The combined organic layers were dried on sodium sulfate, filtered, and the solvent was evaporated in vacuum in a 40 °C water bath. The residue was dissolved in 30 ml of ethanol and during stirring 1.62 ml of 6.8 n hydrogen chloride in ethanol was added. The product immediately crystallized. The suspension was stirred for 5 hours at 0 °C, then filtered, washed with 20 ml of -10 °C ethanol and dried.

Product: 3.2 g (85%) of the title compound (sertraline hydrochloride).

Mp: 246-249 °C.

Claims

1. A process for preparing cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphtalenamine of the formula (I) and its acid addition salts, which comprises the steps of hydrogenating of N-methyl-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphtalene-1-en]-amine-N-oxide of the formula (II) in an inert solvent in the presence of a catalyst, then treating the obtained mixture with alcoholic solution of hydrogen chloride, converting the resulting cis-racemic acid addition salt to the free base by standard techniques skilled in the art, resolving and converting the resulting cis-(+)-base of formula (I) to acid addition salt.

2. A process as claimed in claim 1 wherein the inert solvent is methanol, and the catalyst is Raney-Nickel catalyst in the hydrogenation.

3. A process as claimed in claim 1 wherein the alcoholic solution of inorganic acid is hydrogen chloride in methanol or ethanol.

4. N-methyl- [4- (3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-naphtalene-1-en]-amine-N-oxide of the formula (II).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 97/00083

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C209/40 C07C211/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 030 081 A (PFIZER) 10 June 1981 see page 8 - page 9; claim 3 & US 4 536 518 A cited in the application ---	1
A	US 5 248 699 A (SYSKO ROBERT J ET AL) 28 September 1993 cited in the application see claim 1; examples 1-4 -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

17 March 1998

Date of mailing of the international search report

15. 04. 98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 97/00083

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0030081 A	10-06-81	US 4536518 A	20-08-85
		AT 2668 T	15-03-86
		AU 517357 B	23-07-81
		AU 6389780 A	07-05-81
		BG 60333 B	27-05-94
		CA 1130815 A	31-08-82
		CS 9103542 A	16-12-92
		CS 238609 B	16-12-85
		CS 238617 B	16-12-85
		CS 238618 B	16-12-85
		DD 155615 A	23-06-82
		DK 395280 A,B,	02-05-81
		EG 15527 A	30-04-87
		FI 803398 A	02-05-81
		HK 82284 A	09-11-84
		HR 930199 B	29-02-96
		HR 931527 B	30-04-96
		IN 159644 A	30-05-87
		IN 159643 A	30-05-87
		JP 1287061 C	31-10-85
		JP 56086137 A	13-07-81
		JP 60005584 B	12-02-85
		LU 88330 A	04-05-94
		SI 8012798 A	31-12-94
		SI 8310672 A	30-04-96
		SU 1014467 A	23-04-83
		SU 1034602 A	07-08-83
		ZA 8006726 A	28-10-81

US 5248699 A	28-09-93	JP 6199743 A	19-07-94

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.